- Home
- NOTV vs GPMT Comparison
NOTV vs GPMT Comparison
Compare NOTV & GPMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTV
- GPMT
- Stock Information
- Founded
- NOTV 1974
- GPMT 2015
- Country
- NOTV United States
- GPMT United States
- Employees
- NOTV N/A
- GPMT N/A
- Industry
- NOTV Biotechnology: Pharmaceutical Preparations
- GPMT Real Estate Investment Trusts
- Sector
- NOTV Health Care
- GPMT Real Estate
- Exchange
- NOTV Nasdaq
- GPMT Nasdaq
- Market Cap
- NOTV 137.5M
- GPMT N/A
- IPO Year
- NOTV 1997
- GPMT 2017
- Fundamental
- Price
- NOTV $2.41
- GPMT $2.51
- Analyst Decision
- NOTV Strong Buy
- GPMT Buy
- Analyst Count
- NOTV 3
- GPMT 3
- Target Price
- NOTV $5.92
- GPMT $3.38
- AVG Volume (30 Days)
- NOTV 545.2K
- GPMT 288.8K
- Earning Date
- NOTV 05-09-2025
- GPMT 05-06-2025
- Dividend Yield
- NOTV N/A
- GPMT 7.97%
- EPS Growth
- NOTV N/A
- GPMT N/A
- EPS
- NOTV N/A
- GPMT N/A
- Revenue
- NOTV $475,114,000.00
- GPMT N/A
- Revenue This Year
- NOTV $6.37
- GPMT N/A
- Revenue Next Year
- NOTV $5.74
- GPMT $34.66
- P/E Ratio
- NOTV N/A
- GPMT N/A
- Revenue Growth
- NOTV N/A
- GPMT N/A
- 52 Week Low
- NOTV $1.23
- GPMT $2.46
- 52 Week High
- NOTV $10.19
- GPMT $4.60
- Technical
- Relative Strength Index (RSI)
- NOTV 40.48
- GPMT 29.21
- Support Level
- NOTV $1.98
- GPMT $2.67
- Resistance Level
- NOTV $3.35
- GPMT $2.77
- Average True Range (ATR)
- NOTV 0.31
- GPMT 0.09
- MACD
- NOTV -0.02
- GPMT -0.03
- Stochastic Oscillator
- NOTV 31.39
- GPMT 2.41
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.